Cavion
Manufacturing · Virginia, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
600 E Water St Ste E, Charlottesville, V...Phone Number
(434) 200-8442Website
www.cavionpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Cavion
Cavion, based in Charlottesville, VA and Cambridge, MA, a clinical-stage biotechnology company and now a wholly-owned subsidiary of Jazz, focuses on therapies aimed at modulating the T-type calcium channel for the treatment of chronic and rare neurological diseases. Cavion's portfolio of T-type calcium channel modulators is being developed to restore the brain's natural rhythms in a variety of neurological diseases such as essential tremor, Parkinson's disease tremor, neuropathic pain, and epilepsy with absence seizures.Explore more
Cavion Org Chart
LG
Vice President, Medical Affairs
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cavion your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Cavion is spiking on competitors!
Funding: Get notified immidiatlly once Cavion has new funding data
Click to see if Cavion had a recent Job posting/layoffs
Earning: See what the market has to say on Cavion recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Cavion
Check if Cavion has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Cavion launches new products
Cavion, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Cavion as Masked Content
Find 2 more new buyers
Compare Similar Companies to Cavion
Compare insights from companies similar to Cavion, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cavion is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cavion is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cavion.
Cavion financials insights
Gather financial insights about Cavion, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Private Equity
$5M
2017
Series A
$26.5M
Cavion Tech Stack
A closer look at the technologies used by Cavion
Cavion News & Media
Cavion to Present Results of Phase 2 Essential Tremor Clinical Trial in Platform Presentation at the American Academy of Neurology
CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cavion, Inc., a leading clinical stage biotechnology company committed to developing novel therapeutics for people with neurological diseases, announced today that the results of the Phase 2 study of its lead compound, CX-8998, for essential tremor will be featured in a platform presentation during the American Academy of Neurology 71st Annual Meeting, May 4 to May 10, 2019 in Philadelphia, PA. Cavion is developing oral small moleculeCavion’s T-Type Calcium Channel Modulator CX-8998 is Superior to Current Standard of Care in Suppressing Absence Seizures in a Genetic Epilepsy Model
CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--#Cav3--Cavion presents data that its calcium channel modulator CX-8998 significantly suppresses seizures in GAERS and WAG/Rij rat models of absence epilepsyCavion Announces Promising Phase 2 Data for Essential Tremor in T-CALM Proof-of-Concept Study
HONG KONG--(BUSINESS WIRE)--#MDSCongress--Cavion announces results of Phase 2 study of its first-in-class T-Type calcium channel modulator CX-8998 in essential tremor at MDS 2018 in Hong Kong.Cavion to Announce Results of its Phase 2 Essential Tremor Clinical Trial
CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--#MDSCongress--Cavion, Inc. presents Phase 2 Essential Tremor Trial as late breaker and 3 posters on its T-Type Calcium Channel Modulator CX-8998 at MDS Congress.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cavion
Sign Up For FreeTo access detailed company insights
Cavion, based in Charlottesville, VA and Cambridge, MA, a clinical-stage biotechnology company and now a wholly-owned subsidiary of Jazz, focuses on therapies aimed at modulating the T-type calcium channel for the treatment of chronic and rare neurological diseases. Cavion's portfolio of T-type calcium channel modulators is being developed to resto... Read More
